AnPac Bio Granted Important Novel Micro Medical Device Patent in the United States

安派科 微型医疗设备 专利
Published on: March 25, 2020
Author: Amy Liu

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the allowance by  the United States Patent and Trademark Office on March 5, 2020, of a US patent application claiming an integrated and decomposable micro apparatus that can be used for site-specific delivery of a drug, a medical kit, a micro disease detection system, or even an auto-navigation system for in vivo applications.

“As a leader in using biophysical properties to scan and detect changes in blood and other liquid samples, we wanted to make sure that our technology and patents also include our devices to have the option of being in vivo so that we can constantly test and detect changes in the in the human body,” said Dr. Chris Yu, CEO and Chairman of AnPac Bio. “Due to our fundamental pending and issued patents in the US and many other jurisdictions covering the entire spectrum of disease detection, as well as micro surgical operations and drug release responses, intellectual properties of biophysical measurements with multi-functional micro- medical devices will have significant value in the future.”

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection with two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, AnPac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. AnPac Bio’s CDA technology has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.

For more information, please visit:

Source: Biospace

Healthcare Services Life Science Medical Device Pharmaceutical